Skip to main content
ADIA
OTC Life Sciences

Adia Nutrition Q2 2026: Going Concern Warning, Ineffective Controls, and New Preferred Issuance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.12
Mkt Cap
$11.281M
52W Low
$0.023
52W High
$0.278
52W Position info
426% above low
Off High info
57% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

ADIA has more than doubled off its 52-week low of $0.023.

Summary

Adia Nutrition's Q2 2026 filing shows strong revenue growth but a continued going concern warning, ineffective internal controls, and a subsequent issuance of 2.6 million preferred shares.


Key Events · Earnings and Guidance · ADIA

  • Going Concern Warning Reiterated

    Management states substantial doubt about the company's ability to continue as a going concern, citing a $122,107 net loss for H1 2026 and a $16.1 million accumulated deficit.

  • Revenue Growth Offsets Losses

    Revenue reached $661,660 for the six months ended June 30, 2026, up from $189,910 a year earlier, driven by medical procedures and biologics sales.

  • Ineffective Disclosure Controls

    The company concluded its disclosure controls and procedures were not effective as of June 30, 2026.

  • Subsequent Preferred Share Issuance

    On July 27, 2026, the company issued 2,625,000 Series C Preferred shares to three directors and Cement Factory, adding to potential dilution.


Analysis · ADIA · Life Sciences

Adia Nutrition's Q2 2026 report shows revenue of $661,660 for the first half, up from $189,910 a year earlier, but the company still posted a net loss of $122,107 and carries an accumulated deficit of $16.1 million. Management repeats its going concern warning, stating substantial doubt about the company's ability to continue. The filing also discloses that disclosure controls and procedures were not effective as of June 30, 2026. After quarter-end, the company issued 2,625,000 Series C Preferred shares to three directors and Cement Factory, adding to the overhang from the 67 million potentially dilutive shares already disclosed.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ADIA was trading at $0.12 on OTC in the Life Sciences sector, with a market capitalization of approximately $11.3M. The 52-week trading range was $0.02 to $0.28. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ADIA - Latest Insights

ADIA
Nov 16, 2026, 2:11 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.128
Real-time Price: $0.124 info
Change: -$0.0040 (-3%) info
Market Cap: $11.706M info
ADIA
Oct 19, 2026, 11:22 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.130
Real-time Price: $0.124 info
Change: -$0.0060 (-5%) info
Market Cap: $11.706M info
ADIA
Oct 05, 2026, 7:16 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.101
Real-time Price: $0.124 info
Change: +$0.023 (+23%) info
Market Cap: $11.706M info
ADIA
Oct 05, 2026, 4:49 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.101
Real-time Price: $0.124 info
Change: +$0.023 (+23%) info
Market Cap: $11.706M info
ADIA
May 26, 2026, 8:00 AM EDT
Source: TMX Newsfile
Importance Score:
8
Price at Filing: $0.160
Real-time Price: $0.124 info
Change: -$0.036 (-23%) info
Market Cap: $11.706M info